Relay Therapeutics Company Insiders
RLAY Stock | USD 3.71 0.08 2.20% |
Relay Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Relay Therapeutics suggests that vertually all insiders are panicking. Relay Therapeutics employs about 259 people. The company is managed by 15 executives with a total tenure of roughly 605 years, averaging almost 40.0 years of service per executive, having 17.27 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2025-07-09 | Sanjiv Patel | Disposed 61379 @ 3.57 | View | ||
2025-04-30 | Thomas Catinazzo | Disposed 12943 @ 3 | View | ||
2025-04-28 | Thomas Catinazzo | Disposed 2690 @ 3.17 | View | ||
2025-04-23 | Sanjiv Patel | Disposed 61422 @ 2.97 | View | ||
2025-03-27 | Thomas Catinazzo | Disposed 4864 @ 2.84 | View | ||
2025-02-13 | Sanjiv Patel | Disposed 75324 @ 3.7 | View | ||
2025-02-11 | Sanjiv Patel | Disposed 140182 @ 3.85 | View | ||
2025-01-30 | Peter Rahmer | Disposed 17250 @ 4.42 | View | ||
2025-01-28 | Peter Rahmer | Disposed 1673 @ 4.63 | View | ||
2025-01-22 | Sanjiv Patel | Disposed 125000 @ 4.8 | View | ||
2025-01-06 | Peter Rahmer | Disposed 16576 @ 4.45 | View | ||
2025-01-02 | Peter Rahmer | Disposed 32156 @ 4.15 | View | ||
2024-12-27 | Thomas Catinazzo | Disposed 4865 @ 4.42 | View | ||
2024-12-16 | Sanjiv Patel | Disposed 100000 @ 5 | View |
Monitoring Relay Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relay Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. Relay Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Relay Therapeutics' future performance. Based on our forecasts, it is anticipated that Relay will maintain a workforce of slightly above 260 employees by August 2025.Relay Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2882) % which means that it has lost $0.2882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4546) %, meaning that it created substantial loss on money invested by shareholders. Relay Therapeutics' management efficiency ratios could be used to measure how well Relay Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2025. Return On Capital Employed is likely to drop to -0.48 in 2025. At this time, Relay Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 29.3 M in 2025, whereas Total Assets are likely to drop slightly above 855.6 M in 2025.Common Stock Shares Outstanding is likely to drop to about 89.5 M in 2025. Net Loss is likely to drop to about (274.5 M) in 2025
Relay Therapeutics Workforce Comparison
Relay Therapeutics is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,974. Relay Therapeutics holds roughly 259 in number of employees claiming about 9% of equities under Health Care industry.
Relay Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Relay Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Relay Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Relay Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-06-01 | 0.75 | 9 | 12 | 1,251,327 | 138,865 |
2025-03-01 | 0.4 | 10 | 25 | 3,256,288 | 917,139 |
2024-09-01 | 0.1176 | 2 | 17 | 86,706 | 238,532 |
2024-06-01 | 0.7692 | 10 | 13 | 762,033 | 141,061 |
2024-03-01 | 0.625 | 5 | 8 | 1,662,360 | 10,522 |
2023-06-01 | 0.8462 | 11 | 13 | 628,755 | 25,881 |
2023-03-01 | 0.6842 | 13 | 19 | 1,819,340 | 211,645 |
2022-12-01 | 0.2857 | 6 | 21 | 72,000 | 222,360 |
2022-09-01 | 0.1481 | 4 | 27 | 137,138 | 253,984 |
2022-06-01 | 1.25 | 15 | 12 | 530,978 | 59,543 |
2022-03-01 | 0.6875 | 11 | 16 | 1,046,120 | 115,097 |
2021-12-01 | 0.3077 | 4 | 13 | 30,316 | 308,947 |
2021-09-01 | 0.2857 | 2 | 7 | 29,000 | 59,232 |
2021-06-01 | 0.8333 | 10 | 12 | 173,742 | 213,370 |
2021-03-01 | 0.7368 | 14 | 19 | 854,905 | 5,872,394 |
2020-09-01 | 0.3 | 15 | 50 | 45,728,592 | 152,763,974 |
Relay Therapeutics Notable Stakeholders
A Relay Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Relay Therapeutics often face trade-offs trying to please all of them. Relay Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Relay Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David Shaw | Founder | Profile | |
Matthew Jacobson | Founder | Profile | |
Dorothee Kern | Founder | Profile | |
Deborah Palestrant | Vice Strategy | Profile | |
MA MBA | Pres CEO | Profile | |
Thomas Catinazzo | Chief Officer | Profile | |
Andy Porter | Chief Officer | Profile | |
Jim Watters | Chief Research | Profile | |
Mahesh Padval | Chief Officer | Profile | |
Alexis AM | CoFounder Chairman | Profile | |
Peter Rahmer | Chief Officer | Profile | |
Deborah MBA | Vice Strategy | Profile | |
Jeanne Gray | Chief Officer | Profile | |
Mark Murcko | CoFounder Director | Profile | |
Brian JD | Chief Secretary | Profile |
About Relay Therapeutics Management Performance
The success or failure of an entity such as Relay Therapeutics often depends on how effective the management is. Relay Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Relay management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Relay management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.39) | (0.41) | |
Return On Capital Employed | (0.45) | (0.48) | |
Return On Assets | (0.39) | (0.41) | |
Return On Equity | (0.43) | (0.41) |
Please note, the imprecision that can be found in Relay Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Relay Therapeutics. Check Relay Therapeutics' Beneish M Score to see the likelihood of Relay Therapeutics' management manipulating its earnings.
Relay Therapeutics Workforce Analysis
Traditionally, organizations such as Relay Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Relay Therapeutics within its industry.Relay Therapeutics Manpower Efficiency
Return on Relay Therapeutics Manpower
Revenue Per Employee | 38.6K | |
Revenue Per Executive | 667.1K | |
Net Loss Per Employee | 1.3M | |
Net Loss Per Executive | 22.5M | |
Working Capital Per Employee | 2.9M | |
Working Capital Per Executive | 50.6M |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.